Literature DB >> 21095423

Evaluation and treatment of erectile dysfunction.

Maarten Albersen1, Kuwong B Mwamukonda, Alan W Shindel, Tom F Lue.   

Abstract

Erectile dysfunction (ED) is a prevalent and important disease that has been associated with various comorbidities. The evaluation of patients with ED should include a general health assessment followed by a discussion of reversible factors and lifestyle changes that might help preserve erectile capacity. Numerous effective treatment options are currently available. A frank discussion about use and side effects of these therapies is required to optimize success. Although oral pharmacologic treatments can be initiated and monitored by the primary care physician, patients who do not experience response to these treatments may be best served by referral to a sexual medicine specialist for further assessment and consideration of other treatment options. This article discusses the physiology and pathophysiology of erectile function in men, how the primary care physician may address the clinical problem of ED in practice, and when specialty referral is indicated.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21095423     DOI: 10.1016/j.mcna.2010.08.016

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  8 in total

Review 1.  Role of hydrogen sulfide in the physiology of penile erection.

Authors:  Xuefeng Qiu; Jackie Villalta; Guiting Lin; Tom F Lue
Journal:  J Androl       Date:  2011-10-20

2.  Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.

Authors:  Camilla R Madeira; Fernanda S Tonin; Mariana M Fachi; Helena H Borba; Vinicius L Ferreira; Leticia P Leonart; Aline F Bonetti; Rogerio P Moritz; Angela C L B Trindade; Alan G Gonçalves; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  World J Urol       Date:  2020-05-09       Impact factor: 4.226

Review 3.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

4.  Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice.

Authors:  P K Kavoussi; K Heberlein; A C Straub; G J Lowe; J L Oliver; R P Smith; W D Steers; B H Annex; B E Isakson; J J Lysiak
Journal:  Andrologia       Date:  2014-12-29       Impact factor: 2.775

5.  Male Sexual Dysfunction.

Authors:  Danyon Anderson; John Laforge; Maggie M Ross; Robert Vanlangendonck; Jamal Hasoon; Omar Viswanath; Alan D Kaye; Ivan Urits
Journal:  Health Psychol Res       Date:  2022-08-20

6.  Urine-Derived Stem Cells Versus Their Lysate in Ameliorating Erectile Dysfunction in a Rat Model of Type 2 Diabetes.

Authors:  Rania A Galhom; Horeya Erfan Korayem; Mahrous A Ibrahim; Ahmed Abd-Eltawab Tammam; Mohamed Mansour Khalifa; Eman K Rashwan; Manal H Al Badawi
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

7.  Penile alterations at early stage of type 1 diabetes in rats.

Authors:  Mingfang Tao; Cemal Tasdemir; Seda Tasdemir; Ali Shahabi; Guiming Liu
Journal:  Int Braz J Urol       Date:  2017 Jul-Aug       Impact factor: 1.541

8.  Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series.

Authors:  Francois Giuliano; Pierre Denys; Charles Joussain
Journal:  Toxins (Basel)       Date:  2022-04-16       Impact factor: 5.075

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.